The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Gervas Arruga, Javier ^a,b,c,d   Cebolla, Jorge Javier ^c,e   De Blas, Ignacio ^f   Roca, Mercedes ^c,g   Pocovi, Miguel ^d,e   Giraldo, Pilar ^a,b,c,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c Spanish Gaucher Disease Foundation ^*  (Spain)

^d INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f UNIVERSIDAD DE ZARAGOZA   (Spain)

^g International Skeletal Society Radiodiagnostic Center   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; CCL3 PROTEIN, HUMAN; CYTOKINE; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE DISEASE; BONE MARROW BURDEN MRI SCORE; BONE METABOLISM; CHILD; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; BONE DISEASES; COMPLICATION; GENETIC VARIATION; GENETICS; GENOTYPING TECHNIQUE; INFLAMMATION; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE DISEASES; CHEMOKINE CCL3; CHEMOKINE CCL4; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GAUCHER DISEASE; GENETIC VARIATION; GENOTYPING TECHNIQUES; HUMANS; INFLAMMATION; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84929340184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126153     Document Type: Article

References (47)

1. Beutler E, Grabowski G. Gaucher Disease. In: Scriber C, Beudet A, Sly W, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw Hill; 2001. p. 3635-68.
2. Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Haematologica. 2000;85(8):792-9. PMID: 10942924
3. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol. 2002;75 Suppl 1:A2-12. PMID: 12036828
4. Eriksen E, Axelrod D, Melsen F. Bone histology and bone histomorphometry. In: Eriksen E, Axelrod D, Melsen F, editors. Bone Histomorphometry. New York: Raven Press; 1994. p. 33-48.
5. Nguyen TV, Blangero J, Eisman JA. Genetic epidemiological approaches to the search for osteoporosis genes. J Bone Miner Res. 2000;15(3):392-401. PMID: 10750553
6. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev. 2006;20(18):2492-506. PMID: 16980579
7. Goltzman D. Osteolysis and cancer. J Clin Invest. 2001;107(10):1219-20. PMID: 11375409
8. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100(6):2195-202. PMID: 12200385
9. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta. 2007;1772(7):788-96. PMID: 17499484
10. Pavlova EV, Deegan PB, Tindall J, McFarlane I, Mehta A, Hughes D, et al. Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis. 2011;46(1):27-33. doi: 10.1016/j.bcmd.2010. 10.010 PMID: 21075651
11. Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A. 2010;107(45):19473-8. doi: 10.1073/pnas.1003308107 PMID: 20962279
12. DeMayo RF, Haims AH, McRae MC, Yang R, Mistry PK. Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease. AJR Am J Roentgenol. 2008;191(1):115-23. doi: 10.2214/AJR.07.3550 PMID: 18562733
13. Giraldo P, Alfonso P, Irún P, Gort L, Chabás A, Vilageliu L, et al. Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula. Orphanet J Rare Dis. 2012;7:17. doi: 10.1186/1750-1172-7-17 PMID: 22429443
14. Carrascosa A, Fernandez JM, Fernandez C, Ferrandez A, Lopez-Siguero JP, Sanchez E, et al. Spanish growth studies 2008. New anthropometric standards. Endocrinol Nutr. 2008;55(10):484-506. doi: 10.1016/S1575-0922 (08) 75845-5 PMID: 22980464
15. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. PMID: 7941614
16. Roca M, Mota J, Alfonso P, Pocovi M, Giraldo P. S-MRI score: A simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol. 2007;62(1):132-7. PMID: 17161930
17. Giuffrida G, Cingari MR, Parrinello N, Romano A, Triolo A, Franceschino M, et al. Bone turnover markers in patients with type 1 Gaucher disease. Hematol Rep. 2012;4(4):e21. doi: 10.4081/hr.2012.e21 PMID: 23355939
18. Cummings SR, Marcus R, Palermo L, Ensrud KE, Genant HK. Does estimating volumetric bone density of the femoral neck improve the prediction of hip fracture? A prospective study. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1994;9(9):1429-32. PMID: 7817827
19. Bagger YZ, Tankó LB, Alexandersen P, Hansen HB, Qin G, Christiansen C. The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study. Osteoporos Int. 2006;17(3):471-7. PMID: 16261280
20. Sosa M, Saavedra P, Munoz-Torres M, Alegre J, Gomez C, Gonzalez-Macias J, et al. Quantitative ultrasound calcaneus measurements: normative data and precision in the spanish population. Osteoporos Int. 2002;13(6):487-92. PMID: 12107663
21. Cunningham JL, Fordham JN, Hewitt TA, Speed CA. Ultrasound velocity and attenuation at different skeletal sites compared with bone mineral density measured using dual energy X-ray absorptiometry. Br J Radiol. 1996;69(817):25-32. PMID: 8785618
22. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358(22):2355-65. doi: 10.1056/NEJMoa0801197 PMID: 18445777
23. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res. 2002;17(7):1245-55. PMID: 12096838
24. Langdahl BL, Gravholt CH, Brixen K, Eriksen EF. Polymorphisms in the vitamin D receptor gene and bone mass, bone turnover and osteoporotic fractures. Eur J Clin Invest. 2000;30(7):608-17. PMID: 10886301
25. Bustamante M, Nogués X, Enjuanes A, Elosua R, García-Giralt N, Pérez-Edo L, et al. COL1A1, ESR1, VDR and TGFB1 polymorphisms and haplotypes in relation to BMD in Spanish postmenopausal women. Osteoporos Int. 2007;18(2):235-43. PMID: 17021946
26. Greenwood A, Elstein D, Zimran A, Altarescu G. Effect of vitamin D receptor (VDR) genotypes on the risk for osteoporosis in type 1 Gaucher disease. Clin Rheumatol. 2010;29(9):1037-41. doi: 10.1007/s10067-010-1464-9 PMID: 20419464
27. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13(3):325-49. PMID: 9525333
28. Richards JB, Zheng HF, Spector TD. Genetics of osteoporosis from genome-wide association studies: advances and challenges. Nat Rev Genet. 2012;13(8):576-88. doi: 10.1038/nrg3228 PMID: 22805710
29. Gennari L, Merlotti D, De Paola V, Calabrò A, Becherini L, Martini G, et al. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. Am J Epidemiol. 2005;161(4):307-20. PMID: 15692074
30. van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink AP, Arp PP, et al. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet. 2003;12(14):1745-54. PMID: 12837697
31. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266-74. PMID: 9661593
32. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1998;339(11):733-8. PMID: 9731089
33. Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. J Bone Miner Res. 2012;27(8):1839-48. doi: 10.1002/jbmr.1680 PMID: 22692814
34. Sibille A, Eng CM, Kim SJ, Pastores G, Grabowski GA. Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. Am J Hum Genet. 1993;52(6):1094-101. PMID: 8503443
35. Yamamoto H, Miyamoto K, Li B, Taketani Y, Kitano M, Inoue Y, et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J Bone Miner Res. 1999;14(2):240-7. PMID: 9933478
36. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res. 2001;16(7):1256-64. PMID: 11450701
37. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-19. PMID: 9108485
38. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165-76. PMID: 9568710
39. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun. 1998;250(2):229-34. PMID: 9753612
40. Arko B, Prezelj J, Kocijancic A, Komel R, Marc J. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. Maturitas. 2005;51(3):270-9. PMID: 15978970
41. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. Qjm. 1997;90(1):19-25. PMID: 9093585
42. Mucci JM, Scian R, De Francesco PN, Garcia FS, Ceci R, Fossati CA, et al. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-α. Gene. 2012;509(1):51-9. doi: 10.1016/j.gene.2012.07.071 PMID: 23010424
43. Kacher Y, Futerman AH. Impaired IL-10 transcription and release in animal models of Gaucher disease macrophages. Blood Cells Mol Dis. 2009;43(1):134-7. doi: 10.1016/j.bcmd.2009.03.006 PMID: 19380242
44. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112-9. PMID: 12133749
45. Toth J, Szucs FZ, Benko K, Marodi L. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI]. Orv Hetil. 2003;144(16):749-55. PMID: 12778625
46. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005;35(2):259-67. PMID: 16125420
47. Campeau PM, Rafei M, Boivin MN, Sun Y, Grabowski GA, Galipeau J. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009;114(15):3181-90. doi: 10.1182/blood-2009-02-205708 PMID: 19587377